Table 1. Demographics of Patients and Characteristics of Guillain-Barré Syndrome Reports After the Ad26.COV2.S COVID-19 Vaccination (N = 130).
| Demographic and report characteristics | No. (%) |
|---|---|
| Age, ya | |
| No. | 129 |
| Median (IQR) | 56 (45-62) |
| 18-64 | 111 (86.0) |
| ≥65 | 18 (14.0) |
| Sexb | |
| Men | 77 (59.7) |
| Women | 52 (40.3) |
| Seriousnessc | |
| Hospitalized | 122 (93.8) |
| Life-threatening condition | 46 (35.4) |
| Permanent disability | 42 (32.3) |
| Died | 1 (0.8) |
| Relevant medical history | |
| Recent illness (eg, upper respiratory infection, flu-like symptoms, gastroenteritis) | 10 (7.7) |
| Neuropathologic past medical historyd | 9 (6.9) |
| Time to onset of presumptive GBS, de | |
| No. | 129 |
| Median (IQR) | 13 (10-18) |
| ≤21 d after vaccination | 105 (81.4) |
| ≤42 d after vaccination | 123 (95.3) |
| Reported complications of GBS | |
| Respiratory compromise or failure (eg, patient required endotracheal intubation and/or mechanical ventilation) | 18 (13.8) |
| Dysautonomia/hemodynamic instability (eg, labile blood pressure or pulse) | 4 (3.1) |
| Recoveredf | |
| Yes | 15 (13.8) |
| No | 94 (86.2) |
Abbreviation: GBS, Guillain-Barré syndrome.
a
For 1 person, age was unknown.
b
For 1 person, sex was unknown.
c
Death, life-threatening condition, hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, or congenital anomaly or birth defect.7 These designations are defined by the reporter’s input. Serious criteria are not mutually exclusive.
d
For details about relevant comorbidities, please see the Results section.
e
For 1 person, symptom onset time was unknown. For 6 people, the onset time was more than 42 days: 62, 70, 75, 85, 89, or 94 days after vaccination.
f
For 21 people, recovery status was unknown.